9.80
0.07 (0.72%)
| Previous Close | 9.73 |
| Open | 9.68 |
| Volume | 4,077,528 |
| Avg. Volume (3M) | 2,589,818 |
| Market Cap | 2,928,299,008 |
| Price / Earnings (Forward) | 57.80 |
| Price / Sales | 5.54 |
| Price / Book | 15.07 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -21.21% |
| Operating Margin (TTM) | 17.53% |
| Diluted EPS (TTM) | -0.340 |
| Quarterly Revenue Growth (YOY) | 36.70% |
| Total Debt/Equity (MRQ) | 248.66% |
| Current Ratio (MRQ) | 3.15 |
| Operating Cash Flow (TTM) | -26.52 M |
| Levered Free Cash Flow (TTM) | -10.72 M |
| Return on Assets (TTM) | 1.16% |
| Return on Equity (TTM) | -67.09% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Amicus Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.13 |
|
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.76% |
| % Held by Institutions | 104.57% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 21.00 (Cantor Fitzgerald, 114.29%) | Buy |
| Median | 15.00 (53.06%) | |
| Low | 12.00 (Morgan Stanley, 22.45%) | Hold |
| Average | 16.00 (63.27%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 10.76 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 13 Dec 2024 | 12.00 (22.45%) | Hold | 9.36 |
| JP Morgan | 12 Nov 2024 | 17.00 (73.47%) | Buy | 10.49 |
| Cantor Fitzgerald | 07 Nov 2024 | 21.00 (114.29%) | Buy | 10.98 |
| Guggenheim | 07 Nov 2024 | 15.00 (53.06%) | Buy | 10.98 |
| B of A Securities | 17 Oct 2024 | 15.00 (53.06%) | Buy | 11.97 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2025 | Announcement | Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook |
| 02 Jan 2025 | Announcement | Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 06 Nov 2024 | Announcement | Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates |
| 01 Nov 2024 | Announcement | Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 |
| 28 Oct 2024 | Announcement | Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 |
| 17 Oct 2024 | Announcement | Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |